All In Biotech

Drug Trial Radar · NCT05123482

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

A Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD8205 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (BLUESTAR)

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 460 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

460

Planned (sponsor's estimate)

Start

Oct 18, 2021

Primary completion

Sep 29, 2027

Study completion Sep 29, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Nov 17, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents

Conditions

  • Breast Cancer
  • Biliary Tract Carcinoma
  • Ovarian Cancer
  • Endometrial Cancer
  • Squamous Non-Small Cell Lung Cancer

Interventions

  • AZD8205Drug

    AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial cancers and squamous non-small cell lung cancers.

  • AZD8205 and AZD2936 (Rilvegostomig)Drug

    AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial cancers and squamous non-small cell lung cancers. Rilvegostomig is a bispecific antibody that specifically binds to human TIGIT and PD-1 and is a potential anticancer therapy in patients with advanced or metastatic solid tumors.

  • AZD8205 and AZD5305 (saruparib)Drug

    AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial and squamous non-small cell lung cancers. Saruparib is a PARP inhibitor that stops the PARP protein from doing its repair work in damaged cancer cells, resulting in cell death, and is a potential anticancer therapy in patients with advanced or metastatic solid tumors.

  • AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig)Drug

    AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial and squamous non-small cell lung cancers. Saruparib is a PARP inhibitor that stops the PARP protein from doing its repair work in damaged cancer cells, resulting in cell death, and is a potential anticancer therapy in patients with advanced or metastatic solid tumors. Rilvegostomig is a bispecific antibody that specifically binds to human TIGIT and PD-1 and is a potential anticancer therapy in patients with advanced or metastatic solid tumors.

  • AZD8205 in combination with AZD9574Drug

    AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial and squamous non-small cell lung cancers. AZD9574 is a PARP inhibitor that stops the PARP protein from doing its repair work in damaged cancer cells, resulting in cell death, and is a potential anticancer therapy in patients with advanced or metastatic solid tumors.

  • AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936)Drug

    AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial and squamous non-small cell lung cancers. AZD9574 is a PARP inhibitor that stops the PARP protein from doing its repair work in damaged cancer cells, resulting in cell death, and is a potential anticancer therapy in patients with advanced or metastatic solid tumors. Rilvegostomig is a bispecific antibody that specifically binds to human TIGIT and PD-1 and is a potential anticancer therapy in patients with advanced or metastatic solid tumors.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The number of patients with adverse eventsTime frame: From time of Informed consent to 30 days post last dose (approximately 1 year).
  2. The number of patients with serious adverse eventsTime frame: From time of Informed consent to 30 days post last dose (approximately 1 year)
  3. The number of patients with dose-limiting toxicity (DLT), as defined in the protocol.Time frame: From first dose of study treatment until the end of Cycle 1 (approximately 21 days).
  4. The number of patients with changes from baseline laboratory findings, ECGs and vital signsTime frame: From time of informed consent to 30 days post last dose (approximately 1 year)

Locations

67 sites in 15 countries. Site status is shown where the registry gives one.

  • Research Site

    Duarte, California · Completed

  • Research Site

    Irvine, California · Completed

  • Research Site

    Santa Monica, California · Recruiting

  • Research Site

    Santa Rosa, California · Recruiting

  • Research Site

    Shreveport, Louisiana · Completed

  • Research Site

    Baltimore, Maryland · Recruiting

  • Research Site

    Boston, Massachusetts · Recruiting

  • Research Site

    St Louis, Missouri · Recruiting

  • Research Site

    Albuquerque, New Mexico · Recruiting

  • Research Site

    Commack, New York · Recruiting

  • Research Site

    New York, New York · Withdrawn

  • Research Site

    Charlotte, North Carolina · Recruiting

  • Research Site

    Pittsburgh, Pennsylvania · Recruiting

  • Research Site

    Houston, Texas · Recruiting

  • Research Site

    Clayton, Australia · Terminated

  • Research Site

    Melbourne, Australia · Recruiting

  • Research Site

    Nedlands, Australia · Active not recruiting

  • Research Site

    Anderlecht, Belgium · Recruiting

  • Research Site

    Leuven, Belgium · Recruiting

  • Research Site

    Calgary, Alberta, Canada · Recruiting

  • Research Site

    Vancouver, British Columbia, Canada · Recruiting

  • Research Site

    Ottawa, Ontario, Canada · Recruiting

  • Research Site

    Toronto, Ontario, Canada · Recruiting

  • Research Site

    Montreal, Quebec, Canada · Completed

  • Research Site

    Beijing, China · Completed

  • Research Site

    Beijing, China · Recruiting

  • Research Site

    Changsha, China · Terminated

  • Research Site

    Changsha, China · Recruiting

  • Research Site

    Chongqing, China · Recruiting

  • Research Site

    Guangzhou, China · Completed

  • Research Site

    Kunming, China · Recruiting

  • Research Site

    Shandong, China · Recruiting

  • Research Site

    Budapest, Hungary · Withdrawn

  • Research Site

    Budapest, Hungary · Recruiting

  • Research Site

    Budapest, Hungary · Recruiting

  • Research Site

    Milan, Italy · Recruiting

  • Research Site

    Milan, Italy · Recruiting

  • Research Site

    Modena, Italy · Recruiting

  • Research Site

    Roma, Italy · Recruiting

  • Research Site

    Chūōku, Japan · Recruiting

Showing 40 of 67 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.